Merit Medical Systems stock hits 52-week low at $81.00

Merit Medical Systems (MMSI) recently reached a 52-week low of $81.00, reflecting broader sector pressures, despite maintaining a 'GOOD' financial health score. However, the company reported robust Q2 2025 earnings, with EPS of $1.01 and revenue of $382.5 million significantly surpassing analyst expectations, alongside improved organic revenue growth of 6.7%. Analysts, including Needham, reiterated Buy ratings and bullish outlooks, citing the strong performance and suggesting the stock is undervalued, further supported by recent EU approval for its Embosphere Microspheres.

Analysis

Merit Medical Systems (MMSI) presents a significant disconnect between its recent market performance and underlying fundamentals. The stock's descent to a 52-week low of $81.00, marking a 15.51% year-over-year decline, reflects broad medical device sector headwinds. However, this price action is contradicted by robust operational results and a strong financial position. The company reported a substantial second-quarter 2025 earnings beat, with an EPS of $1.01 surpassing consensus by 18.82%, and revenue of $382.5 million exceeding estimates. Critically, organic revenue growth accelerated to 6.7% year-over-year, up from 6.0% in the prior quarter, indicating strengthening business momentum. This performance is supported by a solid balance sheet, evidenced by liquid assets covering short-term obligations by a factor of 4.1x. Forward-looking catalysts further bolster the bull case, including the recent European Union approval for its Embosphere Microspheres in a new application for knee osteoarthritis, opening a new potential market. This fundamental strength has led analysts, such as Needham, to reiterate a 'Buy' rating with a $108.00 price target, underscoring a view that the stock is currently undervalued relative to its performance and prospects.

Key Decisions for Investors

• The pronounced divergence between the stock's 52-week low and the company's strong Q2 earnings beat and accelerating organic growth may present a compelling entry point for value-oriented investors.
• Investors should monitor the commercial rollout and initial revenue impact of the newly EU-approved Embosphere Microspheres for knee osteoarthritis, as this represents a key near-term catalyst for a potential stock re-rating.
• Despite strong fundamentals, the stock's sensitivity to broader sector pressures warrants consideration; therefore, any position should account for ongoing volatility within the medical device industry.